These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 21884002)

  • 1. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge.
    Fung EC; Crook MA
    Cardiovasc Ther; 2012 Oct; 30(5):e212-8. PubMed ID: 21884002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muscle symptoms associated with statins: a series of twenty patients.
    Soininen K; Niemi M; Kilkki E; Strandberg T; Kivistö KT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):51-4. PubMed ID: 16433891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability.
    Golightly LK; Barber GR; Barron MA; Page RL
    Drug Metabol Drug Interact; 2013; 28(1):49-58. PubMed ID: 23314530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing statin-induced muscle toxicity in a lipid clinic.
    Blaier O; Lishner M; Elis A
    J Clin Pharm Ther; 2011 Jun; 36(3):336-41. PubMed ID: 21414023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin induced myopathy.
    Frank RE
    J Insur Med; 2009; 41(2):132-5. PubMed ID: 19845216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing statin myopathy.
    Venero CV; Thompson PD
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):121-36. PubMed ID: 19217515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in 45 patients with statin-associated myopathy.
    Hansen KE; Hildebrand JP; Ferguson EE; Stein JH
    Arch Intern Med; 2005 Dec 12-26; 165(22):2671-6. PubMed ID: 16344427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing the underestimated risk of statin-associated myopathy.
    Rallidis LS; Fountoulaki K; Anastasiou-Nana M
    Int J Cardiol; 2012 Sep; 159(3):169-76. PubMed ID: 21813193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Creatine kinase increase under simvastatin--therapeutic consequences?].
    Rasche-Schürmann CC; Picksak G; Stichtenoth DO
    Med Monatsschr Pharm; 2008 Jan; 31(1):25-7. PubMed ID: 18522017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization.
    Shanahan RL; Kerzee JA; Sandhoff BG; Carroll NM; Merenich JA
    Pharmacotherapy; 2005 Mar; 25(3):345-51. PubMed ID: 15843281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin.
    Zuccaro P; Mombelli G; Calabresi L; Baldassarre D; Palmi I; Sirtori CR
    Pharmacol Res; 2007 Apr; 55(4):310-7. PubMed ID: 17289397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
    Stein EA; Ballantyne CM; Windler E; Sirnes PA; Sussekov A; Yigit Z; Seper C; Gimpelewicz CR
    Am J Cardiol; 2008 Feb; 101(4):490-6. PubMed ID: 18312764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients.
    Berta E; Harangi M; Zsíros N; Nagy EV; Paragh G; Bodor M
    Pharmazie; 2014 Jun; 69(6):420-3. PubMed ID: 24974574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk identification and possible countermeasures for muscle adverse effects during statin therapy.
    Magni P; Macchi C; Morlotti B; Sirtori CR; Ruscica M
    Eur J Intern Med; 2015 Mar; 26(2):82-8. PubMed ID: 25640999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center.
    Karimi S; Hough A; Beckey C; Parra D
    J Manag Care Pharm; 2010 Sep; 16(7):472-81. PubMed ID: 20726676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin-induced myopathy: a review and update.
    Abd TT; Jacobson TA
    Expert Opin Drug Saf; 2011 May; 10(3):373-87. PubMed ID: 21342078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential association between statin exposure and elevated levels of creatine kinase.
    Chan J; Hui RL; Levin E
    Ann Pharmacother; 2005 Oct; 39(10):1611-6. PubMed ID: 16160000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition.
    Hu M; Mak VW; Tomlinson B
    J Clin Pharm Ther; 2011 Jun; 36(3):419-25. PubMed ID: 21545622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin induced myopathy does not show up in MIBI scintigraphy.
    Lupattelli G; Palumbo B; Sinzinger H
    Nucl Med Commun; 2001 May; 22(5):575-8. PubMed ID: 11388581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.